Neximmune EBIT

Neximmune (NEXI) currently reports a EBIT of $-3.5B as of June 2024. That compares with $-50M in the prior-year period — down 6994.7% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Neximmune's EBIT history and peer comparisons.

Neximmune's EBIT decreased from $-50M to $-3.5B — a 6994.7% year-over-year decrease (period ending June 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Neximmune's EBIT of $-3.5B is lower than the Healthcare sector average of $23B. That is roughly 115.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Neximmune reported $-3.5B in EBIT as of June 2024. That compares with $-50M in the prior-year period — down 6994.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-3.5B, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Neximmune, and consider following NEXI for alerts when major investors trade the stock.